Piperacillin Sodium
FDA-approved product (injectable, injection), marketed as Piperacillin, Pipracil.
- Registered studies
- 50+
- Lab records
- 245
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Appendicitis
- Bacterial disease
- Cellulitis
- Diabetic foot
- Endometritis
- Pelvic Inflammatory Disease
- Peritonitis
- Pneumonia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Penicillins with extended spectrum
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CA12
Repurposing investigation
Piperacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA92.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 6 of 12 lab records
- E. coli: measured active in 10 of 42 lab records
- K. pneumoniae: measured active in 30 of 191 lab records
Show the latest 150 of 245 laboratory records, with sources
Loading records…
Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Piperacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION
NCT02917486 · start 2016-01
Registered record
- Registry ID
- NCT02917486
- Conditions
- Infection
- Interventions
- blood sample
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2016-01
- Completion
- 2019-07
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionInterventionblood samplePhaseNot recordedRegistry statusCompletedPiperacillin PK Analysis in Severe Sepsis Patients
NCT02569086 · start 2015-11-01
Registered record
- Registry ID
- NCT02569086
- Conditions
- Sepsis; Severe Sepsis
- Interventions
- Blood draw
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-11-01
- Completion
- 2016-06-30
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSepsis; Severe SepsisInterventionBlood drawPhaseNot recordedRegistry statusCompletedBioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients
NCT03410771 · start 2015-10-01
Registered record
- Registry ID
- NCT03410771
- Conditions
- Electric Impedance; Pharmacokinetics; Capillary Leak Syndrome
- Interventions
- Monitor antibiotic exposure (PK profile); Bioelectrical impedance analysis to measure body composition
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-10-01
- Completion
- 2016-06-01
- Enrolment
- 68
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionElectric Impedance; Pharmacokinetics; Capillary Leak SyndromeInterventionMonitor antibiotic exposure (PK profile); Bioelectrical impedance analysis to measure body compositionPhaseNot recordedRegistry statusCompletedTrial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
NCT02437045 · start 2015-04
Registered record
- Registry ID
- NCT02437045
- Conditions
- Bloodstream Infections
- Interventions
- Meropenem; Piperacillin-tazobactam combination product
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2020-12-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBloodstream InfectionsInterventionMeropenem; Piperacillin-tazobactam combination productPhasePhase 4Registry statusCompletedPiperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
NCT01714570 · start 2012-11
Registered record
- Registry ID
- NCT01714570
- Conditions
- Febrile; Neutropenia; Hematopoietic Stem Cell Transplantation
- Interventions
- Piperacillin-tazobactam combination product; Imipenem
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2014-04
- Enrolment
- 123
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFebrile; Neutropenia; Hematopoietic Stem Cell TransplantationInterventionPiperacillin-tazobactam combination product; ImipenemPhaseNot applicableRegistry statusCompletedInitial Antibiotics and Delayed Appendectomy for Acute Appendicitis
NCT01697059 · start 2012-09
Registered record
- Registry ID
- NCT01697059
- Conditions
- Acute Appendicitis
- Interventions
- Piperacillin + Amoxicillin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2015-05
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute AppendicitisInterventionPiperacillin + AmoxicillinPhaseNot applicableRegistry statusCompletedPharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients
NCT01517815 · start 2012-02
Registered record
- Registry ID
- NCT01517815
- Conditions
- Septic Shock
- Interventions
- Doripenem or Piperacillin/Tazobactam; Doripenem or Piperacillin/Tazobactam
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2013-06
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeptic ShockInterventionDoripenem or Piperacillin/Tazobactam; Doripenem or Piperacillin/TazobactamPhaseNot applicableRegistry statusCompletedPiperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
NCT01897831 · start 2011-08
Registered record
- Registry ID
- NCT01897831
- Conditions
- Respiratory Tract Infections; Urinary Tract Infections
- Interventions
- xin te mie
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2011-08
- Completion
- 2015-11
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRespiratory Tract Infections; Urinary Tract InfectionsInterventionxin te miePhasePhase 4Registry statusUnknownAntimicrobial Prophylaxis in Thyroid and Parathyroid Surgery
NCT01805856 · start 2010-11
Registered record
- Registry ID
- NCT01805856
- Conditions
- Thyroid Disease; Parathyroid Disease
- Interventions
- PIPC piperacillin sodium; CEZ, cefazolin sodium
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2012-05
- Enrolment
- 2,164
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThyroid Disease; Parathyroid DiseaseInterventionPIPC piperacillin sodium; CEZ, cefazolin sodiumPhaseNot applicableRegistry statusCompletedRole of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor
NCT01290003 · start 2010-06
Registered record
- Registry ID
- NCT01290003
- Conditions
- Neonatal Sepsis
- Interventions
- Piperacillin-Tazobactam and Amikacin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2011-01
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeonatal SepsisInterventionPiperacillin-Tazobactam and AmikacinPhaseNot applicableRegistry statusCompletedPiperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis
NCT02619149 · start 2009-03
Registered record
- Registry ID
- NCT02619149
- Conditions
- Cholecystitis, Acute
- Interventions
- Piperacillin-tazobactam combination product; Saline solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2018-01
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholecystitis, AcuteInterventionPiperacillin-tazobactam combination product; Saline solutionPhasePhase 3Registry statusCompletedStandard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock
NCT00816790 · start 2009-01
Registered record
- Registry ID
- NCT00816790
- Conditions
- Septic Shock; Acute Renal Failure
- Interventions
- Piperacillin/Tazobactam; Piperacillin/Tazobactam
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2009-01
- Completion
- 2011-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeptic Shock; Acute Renal FailureInterventionPiperacillin/Tazobactam; Piperacillin/TazobactamPhasePhase 4Registry statusTerminatedRisk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
NCT00573521 · start 2007-11
Registered record
- Registry ID
- NCT00573521
- Conditions
- Enterobacteriaceae Infections
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-11
- Completion
- 2017-06
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEnterobacteriaceae InfectionsInterventionNot recordedPhaseNot recordedRegistry statusCompletedEffects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
NCT00634166 · start 2007-09
Registered record
- Registry ID
- NCT00634166
- Conditions
- Burns
- Interventions
- Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2007-09
- Completion
- 2014-04
- Enrolment
- 220
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBurnsInterventionSulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal MedicationsPhasePhase 4Registry statusTerminatedTazocin Intervention Study
NCT00478855 · start 2006-09
Registered record
- Registry ID
- NCT00478855
- Conditions
- Bacterial Infections
- Interventions
- Tazocin (Piperacillin/Tazobactem)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2007-06
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial InfectionsInterventionTazocin (Piperacillin/Tazobactem)PhasePhase 4Registry statusCompleted